Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYR-210 in Chronic Rhinosinusitis (ENLIGHTEN 1)
NCT05219968Phase 3Completed
- Sponsor
- Lyra Therapeutics, Inc.
- Start
- Jan 2022
- Primary completion
- Mar 2024
- Modality
- Polymer-based Nanoparticles, Device-based Delivery, Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of LYR-210 in chronic rhinosinusitis (CRS), sponsored by Lyra Therapeutics, Inc.. Started Jan 2022; status: completed.
02
Drugs
LYR-210
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT05219968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05219968.